ArticleBlood cancer journal2026

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.

Ricardo D Parrondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.